Welcome to our dedicated page for Orchestra BioMed Holdings Ordinary Shares news (Ticker: $OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orchestra BioMed Holdings Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orchestra BioMed Holdings Ordinary Shares's position in the market.
Orchestra BioMed announced that its AVIM Therapy Global Intellectual Property Estate has reached 110 issued patents worldwide, with 37 in the U.S. and 73 internationally. The patents cover over 1,800 claims related to hypertension treatment. The company is currently studying AVIM therapy in the BACKBEAT global pivotal study with Medtronic. Orchestra BioMed will provide an overview of AVIM therapy and the study on June 11, 2024, at an R&D day in New York City.
Orchestra BioMed, a biomedical company, will host an R&D day in New York on June 11, 2024, to discuss their AVIM therapy program for hypertensive pacemaker patients. Key opinion leaders will present on the program's mechanism of action, clinical evidence, and study design.